Drug Information

Drug General Information
Drug ID
D0Z6UC
Former ID
DAP000219
Drug Name
Sumatriptan
Synonyms
Imigran; Imitrex; Sumatran; Sumatriptanum; Sumax; GR 43175; GR 43175X; NP101; GR-43175; Imigran (TN); Imitrex (TN); KS-1116; Sumatriptanum [INN-Latin]; Sumatriptan (JAN/USP/INN); (3-[2-(Dimethylamino)ethyl]-1H-indol-5-yl)-N-methylmethanesulfonamide; 1-[3-(2-dimethylaminoethyl)-1H-indol-5-yl]-N-methyl-methanesulfonamide; 1-[3-(2-dimethylaminoethyl)-1H-indol-5-yl]-N-methylmethanesulfonamide; 1-{3-[2-(dimethylamino)ethyl]-1H-indol-5-yl}-N-methylmethanesulfonamide; 3-(2-(Dimethylamino)ethyl)-N-methyl-1H-indole-5-methanesulfonamide; 3-[2-(Dimethylamino)ethyl]-N-methyl-1H-indole-5-methanesulfonamide; 3-[2-(Dimethylamino)ethyl]-N-methylindole-5-methanesulfonamide
Drug Type
Small molecular drug
Indication Migraine headaches [ICD9: 346; ICD10:G43] Approved [536361], [540805]
Therapeutic Class
Vasoconstrictor Agents
Company
GlaxoSmithKline
Structure
Download
2D MOL

3D MOL
Formula
C14H21N3O2S
InChI
InChI=1S/C14H21N3O2S/c1-15-20(18,19)10-11-4-5-14-13(8-11)12(9-16-14)6-7-17(2)3/h4-5,8-9,15-16H,6-7,10H2,1-3H3
InChIKey
KQKPFRSPSRPDEB-UHFFFAOYSA-N
CAS Number
CAS 103628-46-2
PubChem Compound ID
5358
PubChem Substance ID
9527, 5634131, 7847517, 7980713, 8153293, 10502764, 14718471, 14825017, 25819952, 26612933, 26749855, 29224410, 46506520, 48334598, 48416587, 49679316, 49984205, 50107736, 50422744, 53790264, 56322605, 57322735, 81040912, 85209322, 85789242, 93166406, 103188807, 103919260, 104309008, 119526324, 124799677, 125336887, 126525330, 126667002, 128419875, 134337534, 135018088, 135651095, 137002439, 142467611, 144205081, 152034343, 160964014, 162182413, 164814822, 165699400, 170465377, 172866507, 174006309, 175265694
ChEBI ID
ChEBI:10650
SuperDrug ATC ID
N02CC01
SuperDrug CAS ID
cas=103628462
Target and Pathway
Target(s) 5-hydroxytryptamine 1D receptor Target Info Agonist [534894], [534966], [535146], [535803], [538154]
KEGG Pathway cAMP signaling pathway
Neuroactive ligand-receptor interaction
Serotonergic synapse
PANTHER Pathway Heterotrimeric G-protein signaling pathway-Gi alpha and Gs alpha mediated pathway
5HT1 type receptor mediated signaling pathway
Reactome Serotonin receptors
G alpha (i) signalling events
WikiPathways Serotonin HTR1 Group and FOS Pathway
Monoamine GPCRs
GPCRs, Class A Rhodopsin-like
GPCR ligand binding
GPCR downstream signaling
References
Ref 536361Natural products as sources of new drugs over the last 25 years. J Nat Prod. 2007 Mar;70(3):461-77. Epub 2007 Feb 20.
Ref 540805(http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 54).
Ref 5348945-Hydroxytryptamine(1F) receptors do not participate in vasoconstriction: lack of vasoconstriction to LY344864, a selective serotonin(1F) receptor agonist in rabbit saphenous vein. J Pharmacol Exp Ther. 1999 Sep;290(3):935-9.
Ref 534966Novel approaches to the treatment of nausea and vomiting. Dig Dis. 1999;17(3):125-32.
Ref 535146Irritable bowel syndrome: new agents targeting serotonin receptor subtypes. Drugs. 2001;61(3):317-32.
Ref 5358035-Hydroxytryptamine receptor agonists for the abortive treatment of vascular headaches block mast cell, endothelial and platelet activation within the rat dura mater after trigeminal stimulation. Brain Res. 1992 Jun 26;583(1-2):137-49.
Ref 538154Serotonin in migraine: theories, animal models and emerging therapies. Prog Drug Res. 1998;51:219-44.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.